UEM EDGENTA BERHAD Integrated Annual Report 2025 328 NOTES TO THE FINANCIAL STATEMENTS For the year ended 31 December 2025 19. INVESTMENT IN ASSOCIATES (CONTD.) (ii) Summarised statements of comprehensive income Biomedix One Medicare Sedafiat 2025 RM’000 2024 RM’000 2025 RM’000 2024 RM’000 2025 RM’000 2024 RM’000 Revenue 62,189 59,272 234,256 225,090 247,948 265,027 Profit before tax 23,842 19,759 5,654 4,414 10,014 10,771 Profit for the year, representing total comprehensive income 17,662 14,406 3,873 2,633 6,594 7,658 Dividend received from the associates during the year 3,360 2,076 520 278 3,200 3,200 (iii) Reconciliation of the summarised financial information presented above to the carrying amount of the Group’s interest in associates Biomedix One Medicare Sedafiat 2025 RM’000 2024 RM’000 2025 RM’000 2024 RM’000 2025 RM’000 2024 RM’000 Net assets at 1 January 76,104 66,888 37,049 35,111 67,171 67,513 Profit for the year 17,662 14,406 3,873 2,633 6,594 7,658 Dividend declared (8,400) (5,190) (1,300) (695) (8,000) (8,000) Net assets at 31 December 85,366 76,104 39,622 37,049 65,765 67,171 Interest in associates 40% 40% 40% 40% 40% 40% Carrying value of Group’s interest in material associate 34,146 30,442 15,849 14,820 26,306 26,868 20. INVESTMENT IN JOINT VENTURES Group 2025 RM’000 2024 RM’000 Unquoted shares, at cost In Malaysia 152 122 Outside Malaysia 1,326 - 1,478 122 Share of post-acquisition reserves 213 40 1,691 162
RkJQdWJsaXNoZXIy NDgzMzc=